In ₹ Crore except Per Share Latest Annual	SGRL FY26	BPLPHARMA FY23	JENBURPH FY26	KPL FY24	Peer Average
Valuation — at last close
P/E	47.54×	◆ 45.39×	—	—	45.39× +5%
P/B	◆ 5.18×	5.78×	—	—	5.78× -10%
EV/EBITDA	◆ 24.27×	51.68×	—	—	51.68× -53%
Market Cap	₹845 Cr	₹1,105 Cr	—	—	₹1,105 Cr -24%
Growth
Revenue CAGR 3Y	—	—	7.26%	—	7.26%
Revenue CAGR 5Y	—	—	9.07%	—	9.07%
Net Income CAGR 3Y	—	—	12.18%	—	12.18%
Profitability
EBITDA Margin	◆ 32.04%	9.80%	23.81%	21.69%	18.43% +74%
Net Income Margin	16.26%	11.16%	◆ 20.59%	—	15.88% +2%
Return on Common Equity	11.53%	13.63%	◆ 18.84%	—	16.23% -29%
Return on Capital Employed	13.57%	—	—	◆ 19.78%	19.78% -31%
Return on Assets	8.89%	9.25%	◆ 16.45%	—	12.85% -31%
Credit & Quality
Total Debt/Equity	0.19×	◆ 0.04×	—	0.43×	0.23× -19%
Interest Coverage	6.89×	◆ 7.10×	—	4.54×	5.82× +18%
Scale — latest FY
Revenue / Total Income	₹109 Cr	₹218 Cr	₹169 Cr	₹307 Cr	₹231 Cr -53%
Net Income	₹17.8 Cr	₹24.3 Cr	₹34.7 Cr	—	₹29.5 Cr -40%
Total Assets	₹208 Cr	₹308 Cr	₹226 Cr	₹398 Cr	₹311 Cr -33%
EPS	₹13.84	₹42.14	—	—	₹42.14 -67%
Book Value per Share	₹126.94	₹330.83	—	—	₹330.83 -62%

◆ best value in the comp set per metric · Δ = subject vs average of the other companies.

« ‹ › »Latest: FY26 · StandaloneFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 85%.